Article

MRTX1133 is a potent non-covalent KRAS (G12C) inhibitor with tissue-specific activity

2025-09-14

Abstract excerpt

KRAS is a high-value therapeutic target for the treatment of cancer. Two covalent inhibitors, sotorasib and adagrasib, which target a specific codon 12 mutation (G12C), have received accelerated approvals for clinical use. Studies of these inhibitors ushered in the development of new inhibitors such as MRTX1133, that had entered clinical trials as a KRAS (G12D)-selective, non-covalent inhibitor. However, the subse...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a30b0a78-8e16-5db2-b44a-5a89488a6805
DOI: 10.1101/2025.09.09.674973

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MRTX1133 is a potent non-covalent KRAS (G12C) inhibitor with tissue-specific activityDOI 10.1101/2025.09.09.674973Read

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read

Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.Semantic proximity Read

KRAS inhibitors: going noncovalent.Semantic proximity Read

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.Semantic proximity Read

Targeting KRAS G12C with Covalent InhibitorsSemantic proximity Read

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.Semantic proximity Read

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity Read

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read

A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133Semantic proximity Read

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity Read